OXFD - Oxford Immunotec Global PLC

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Oxford Immunotec Global PLC

143 Park Drive
Milton Park
Abingdon OX14 4SE
United Kingdom
44 1235 442 780

IndustryDiagnostics & Research
Full Time Employees243

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter Wrighton-SmithCEO & Exec. Director1.11MN/A1974
Mr. Matthew T.E. McLaughlinChief Financial Officer527.45kN/A1977
Ms. Janet Louise KiddGen. Counsel & Company Sec.N/AN/AN/A
Dr. Peter EdwardsonSr. VP & Head of Blood ScreeningN/AN/A1962
Mr. Jeff R. SchroederPres, Strategic AccountsN/AN/A1961
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

Corporate Governance

Oxford Immunotec Global PLC’s ISS Governance QualityScore as of December 5, 2019 is 6. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.